After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Shares of Durata Therapeutics (DRTX) soared to a 52-week high on Monday after Actavis (ACT) agreed to purchase the pharmaceutical company for approximately $675 million.
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Antibiotic-resistant 'superbugs' are spreading, and drug companies and their investors should take notice.
Here's a list of 34 FDA drug approval decisions and scheduled advisory panels from December 31 through October 2014.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.